CIRCULATING TUMOR DNA AS A CLINICAL TEST IN RESECTED PANCREATIC CANCER.
In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology (CAP) certified clinical laboratory. ctDNA was detected pre-operatively in 29 (49%) […]
CIRCULATING TUMOR DNA AS A CLINICAL TEST IN RESECTED PANCREATIC CANCER. Read More »
